In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

A shortened, all-oral drug regimen worked well for some patients with pre-extensively drug-resistant tuberculosis (pre-XDR TB ...

NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage pioneer in host-mimetic nanomedicine, affirmed its preparedness to address the continued ...

NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage innovator in broad-spectrum antivirals, announced near-finalization of its adaptive clin ...

Market OverviewThe global Epilepsy Drugs Market is valued at USD 10.63 billion in 2024 and is projected to reach a value ...

Does colchicine work for CVD or doesn’t it? That’s the question the study authors hoped to answer, but there’s little ...

Antibiotic resistance is one of the world's leading causes of death, claiming the lives of more people than HIV / AIDS or ...

FDA grants full approval to Moderna's COVID-19 vaccine for children aged 6 months to 11 years with medical vulnerabilities, ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...